Literature DB >> 24114241

Review of new guidelines for the management of glucocorticoid induced osteoporosis.

Swamy R Venuturupalli1, Wendy Sacks.   

Abstract

The chronic use of glucocorticoids results in osteoporosis. Several sets of guidelines have been published on the management of glucocorticoid induced osteoporosis (GIO). These guidelines vary on their focus and highlight different aspects of the current concepts in the management of GIO. In this current article, we summarize recent guidelines for management of GIO and highlight similarities and differences as well as address some of the controversies generated by these guidelines.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24114241     DOI： 10.1007/s11914-013-0170-3

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN： 1544-1873            Impact factor:   5.096


  55 in total

1.  Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.

Authors:  Shinichi Nagase; Yoshitaka Hashimoto; Maria Small; Michiyo Ohyama; Tomohiro Kuwayama; Steve Deacon
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

2.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Authors:  Wei Yao; Zhiqiang Cheng; Cheryl Busse; Aaron Pham; Mary C Nakamura; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-06

Review 3.  Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis.

Authors:  A Cranney; V Welch; J D Adachi; J Homik; B Shea; M E Suarez-Almazor; P Tugwell; G Wells
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 4.  Inhibition of cathepsin K for treatment of osteoporosis.

Authors:  Steven Boonen; Elizabeth Rosenberg; Frank Claessens; Dirk Vanderschueren; Socrates Papapoulos
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

5.  Influence of glucocorticoids on human osteoclast generation and activity.

Authors:  Sutharshani Sivagurunathan; Meloni M Muir; Tara C Brennan; J Paul Seale; Rebecca S Mason
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

6.  Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; J Preuss
Journal:  Rheumatology (Oxford)       Date:  2003-04-16       Impact factor: 7.580

7.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

8.  Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.

Authors:  Robin K Dore; Stanley B Cohen; Nancy E Lane; William Palmer; William Shergy; Lifen Zhou; Huei Wang; Wayne Tsuji; Richard Newmark
Journal:  Ann Rheum Dis       Date:  2009-09-03       Impact factor: 19.103

9.  Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; F Sorenson
Journal:  Osteoporos Int       Date:  2003-08-28       Impact factor: 4.507

10.  Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ana Patrícia Paula; Cristiano Zerbini; Diogo S Domiciano; Helenice Gonçalves; Jaime S Danowski; João F Marques Neto; Laura M C Mendonça; Mailze C Bezerra; Maria Teresa Terreri; Marta Imamura; Pedro Weingrill; Perola G Plapler; Sebastião Radominski; Tatiana Tourinho; Vera L Szejnfeld; Nathalia C Andrada
Journal:  Rev Bras Reumatol       Date:  2012-08
View more
  1 in total

Review 1.  Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives.

Authors:  Xiao Lin; Dan Xiong; Yi-Qun Peng; Zhi-Feng Sheng; Xi-Yu Wu; Xian-Ping Wu; Feng Wu; Ling-Qing Yuan; Er-Yuan Liao
Journal:  Clin Interv Aging       Date:  2015-06-25       Impact factor: 4.458
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.